Abilify
Product Images NDC 68151-4461

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 68151-4461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Chemical Structure (Abilify Chemical Structure)

Chemical structure of the active ingredient in ABILIFY, showing a bicyclic aromatic system with two chlorine atoms attached, a piperazine ring, and an ether-linked side chain ending in a ketone functional group.*

FDA Label Image

Figure 1 (Abilify Figure 1)

A chart titled 'Effect of Other Drugs on Abilify' showing aripiprazole fold change and 90% confidence intervals. The chart compares AUC and Cmax values of aripiprazole when co-administered with different CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs, indicating their relative impact on aripiprazole pharmacokinetics.*

FDA Label Image

Figure 2 (Abilify Figure 2)

A scatter plot graph titled 'Effect of Other Drugs on Abilify' depicting the fold change and 90% confidence interval of dehydro-aripiprazole pharmacokinetics parameters AUC and Cmax. The x-axis shows change relative to reference (without interacting drug) ranging from 0.0 to 3.0. Various interacting drugs including CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others are listed on the y-axis, each with corresponding data points for AUC and Cmax fold changes.*

FDA Label Image

Figure 3 (Abilify Figure 3)

A chart titled 'Effect of Abilify on Other Drugs' showing fold change and 90% confidence intervals for various drugs and enzymes. The horizontal axis represents the change relative to a reference without interacting drug, ranging from 0.5 to 3. Different drugs and enzymes such as CYP2D6, warfarin, omeprazole, and escitalopram are plotted with points and error bars indicating their pharmacokinetic parameters affected by Abilify.*

FDA Label Image

Figure 4 (Abilify Figure 4)

A forest plot chart illustrating changes in pharmacokinetic parameters (AUC and Cmax) of aripiprazole in various special populations. The x-axis represents change relative to reference, with values ranging from 0.5 to 3.0. The chart compares poor vs. extensive CYP2D6 metabolizers, gender differences, age groups, degrees of hepatic impairment, and severe renal impairment, showing fold change and 90% confidence intervals for each group.*

FDA Label Image

Figure 5 (Abilify Figure 5)

A plot showing fold change and 90% confidence interval of dehydro-aripiprazole pharmacokinetics relative to a reference. The variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with fold change values and confidence intervals depicted on a horizontal scale.*

FDA Label Image

Figure 6 (Abilify Figure 6)

A Kaplan-Meier curve graph displaying the proportion of subjects with relapse over days from randomization, comparing ABILIFY and placebo groups. ABILIFY is represented by a blue solid line, and placebo by a red dashed line. The x-axis shows days from randomization, and the y-axis indicates the proportion with relapse. A table beneath the graph lists the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 7 (Abilify Figure 7)

A Kaplan-Meier survival curve comparing the proportion of subjects experiencing relapse over time between ABILIFY and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse. ABILIFY is represented by a blue solid line and placebo by a red dashed line. Below the x-axis is a table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 8 (Abilify Figure 8)

A Kaplan-Meier survival curve chart depicting the proportion of relapses over days from randomization for two groups: ABILIFY (blue solid line) and Placebo (red dashed line). The x-axis shows days from 0 to 364, and the y-axis shows the proportion with relapse from 0 to 1. The number of subjects at risk is listed below the x-axis for both groups at various time points.*

FDA Label Image

Figure 9 (Abilify Figure 9)

A line graph titled 'Change in YGTSS Total TIC Score from Baseline' showing least squares mean change over 8 weeks of treatment. The x-axis represents weeks of treatment (0 to 8), and the y-axis represents change in YGTSS total TIC score (0 to -20). The graph compares three groups: ARIP-LOW, ARIP-HIGH, and PLACEBO, with both ARIP-LOW and ARIP-HIGH showing greater reductions in tic scores compared to placebo over time.*

FDA Label Image

Otsuka Logo (Abilify Otsuka Logo)

FDA Label Image

Label Image (Lbl681514461)

Label for ABILIFY (aripiprazole) 15 mg tablets, manufactured by Otsuka. The label includes lot number 3H67121, expiration date 08/14, and product code PDM 4461. It features a barcode with the number 0000004461 and indicates prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.